Navigation Links
HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services
Date:12/3/2008

ty Assay Kits and for its Contract Research Services using the HALO(R) Platform.

Ivan Rich, PhD, Founder and CEO of HemoGenix(R), said that, "It has been a pleasure working with ORF. Their response and products have been exceptional. Incorporating these growth factors and cytokines in our HALO(R) Platform products is extremely important for our quality control and potency assays, because we can now use biorisk- and contaminant-free products that provide far greater clinical relevance for the results that are obtained with our kits and services."

Bjorn Orvar, PhD, Co-founder and CEO of ORF Genetics, said that, "ORF Genetics ISOkine(TM) growth factors produced in our Orfeus(TM) plant-based production system are not only a novel approach for producing growth factors, but also a much-needed option for endotoxin-free, and animal- and serum-free components, for cell culture and medical research. HemoGenix(R) is a global leader of developing kits and assays for high throughput and validated cell- based assays for the detection and prediction of hemotoxicity, and we are very pleased to collaborate with HemoGenix(R) for the incorporation of our ISOkine(TM) growth factors and cytokines in its HALO(R) Hemotoxicity Assay Kits and Contract Research Services using the HALO(R) platform."

About HemoGenix(R), Inc

HemoGenix(R) was the first company in the world to provide high throughput and predictive cell-based in vitro assays to detect human hemotoxicity (toxicity to the blood-forming system). The HALO(R) Platform and other proprietary assays (LUMENESC(TM) and LumiSTEM(TM)) for different cell systems share the same ATP-based, in vitro bioluminescence technology. This allows biological responses to virtually any agent to be directly compared with each other across cell systems from different species simultaneously. Since its founding in 2000, HemoGenix(R) has developed its own portfolio of patented assays f
'/>"/>

SOURCE HemoGenix, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
2. Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
3. Enigma Diagnostics Announces the Opening of a United States Office
4. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
5. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
6. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
7. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
10. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
11. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada ... It detects CYP2C19 genetic mutations in less than 60 ... RX CYP2C19 System is the first near-patient DNA test ... Due to the system’s ease of use, Health Canada ... professionals such as doctors, nurses, pharmacists, and laboratory technicians, ...
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and conducted by ... at Indiana,s capital market and ... time frames: 1993 to 2002 and 2003 to 2013.  ... investment growth.  The Life Science Innovation Capital in ... innovation dollars as well as an increase in life ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... by Type (High & Medium), Sub-type (Primary & ... Processing, Infrastructure & Transportation & Power Generation) - ... the GIS market with analysis and forecasting of ... Market Data Tables with 52 Figures spread through ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 New ... SoundConnect , an industry leading unified communication ... partners and agents to deliver cloud-based audio and ... growth opportunities. , With SoundConnect’s Q4 incentive ... twenty-five video and/or web conferencing licenses sold, now ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2
... Data and User Customization -- BUDAPEST, Hungary, August 20, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... Confirms Clinical Efficacy and Safety of Radioembolisation Using... -- BRUSSELS, August 19, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Silence Therapeutics plc (AIM: SLN), a leading international RNAi ... Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of ... license to develop and commercialise QPI-1002, a p53 temporary ... Quark is currently conducting a Phase II clinical ...
Cached Biology Technology:ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 2ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 3ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 4ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 5ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 2Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 4Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 5Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 7Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:10/30/2014)... suite of technologies that can be used to enhance ... everything from search and rescue to service dogs to ... computer-mediated communication between humans and dogs that opens the ... and sending them clear and unambiguous cues in return," ... science at NC State and co-lead author of a ...
(Date:10/29/2014)... Research suggesting air pollutants released by unconventional oil and ... US is published today in the open access journal ... sulfide and formaldehyde were found. The study is the ... who live near production sites and could be used ... and gas come from reserves that do not readily ...
(Date:10/29/2014)... (October 29, 2014, Beaverton, OR) New research ... 11th International Conference in Houston, TX showed for ... eliminate HPV infection in women using a readily ... The study, presented by Dr. Judith A. Smith, ... Gynecology and Reproductive Sciences at The University of ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... of Parkinson,s disease patients had insufficient levels of vitamin ... of Medicine. The fraction of Parkinson,s patients ... than patients with Alzheimer,s disease (41 percent) or healthy ... in the October issue of Archives of Neurology ...
... of their chimpanzee relatives, bonobo societyin which females enjoy ... of image. While chimpanzee males frequently band together to ... believed to restrict what meat they do eat to ... according to a study, reported in the October 14th ...
... of the brain can come under attack in patients with ... with an MS-like disease, the brain,s response to a protein ... cord or cerebellum that comes under fire. The studyfrom researchers ... and Washington University in St. Louiswill be published online on ...
Cached Biology News:Lack of vitamin D linked to Parkinson's disease 2Lack of vitamin D linked to Parkinson's disease 3Despite 'peacenik' reputation, bonobos hunt and eat other primates too 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... been developed for use with immunohistochemical ... nonspecific background staining due to endogenous ... peroxidase with hydrogen peroxide. This ... with additional novel components to further ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: